ChiCTR2600118240 版本V1.0 版本创建时间2026/02/03 16:38:10 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600118240 

最近更新日期:

Date of Last Refreshed on:

2026-02-03 16:38:04 

注册时间:

Date of Registration:

2026-02-03 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

不同止吐药物联合应用对妇科腹腔镜手术术后恶心呕吐的疗效观察

Public title:

The efficacy of different antiemetic drugs combined on postoperative nausea and vomiting in gynecologic laparoscopic surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

不同止吐药物联合应用对妇科腹腔镜手术术后恶心呕吐的疗效观察

Scientific title:

The efficacy of different antiemetic drugs combined on postoperative nausea and vomiting in gynecologic laparoscopic surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李君可 

研究负责人:

李彦东 

Applicant:

Li Junke 

Study leader:

Li Yandong 

申请注册联系人电话:

Applicant telephone:

+86 132 2625 7568

研究负责人电话:

Study leader's
telephone:

+86 186 7876 6855

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

523500732@qq.com

研究负责人电子邮件:

Study leader's E-mail:

mzklyd@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省济宁市任城区荷花路129号

研究负责人通讯地址:

山东省济宁市任城区荷花路129号

Applicant address:

No. 129, Lotus Road, Rencheng District, Jining City, Shandong Province

Study leader's address:

No. 129, Lotus Road, Rencheng District, Jining City, Shandong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

济宁医学院附属医院

Applicant's institution:

The Affiliated Hospital of Jining Medical University

研究负责人所在单位:

济宁医学院附属医院

Affiliation of the Leader:

The Affiliated Hospital of Jining Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-11-C002

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

济医附院医学科学伦理委员会

Name of the ethic committee:

Medical Science Ethics Committee of the Affiliated Hospital of Jining Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-14 00:00:00

伦理委员会联系人:

齐迪

Contact Name of the ethic committee:

Qi Di

伦理委员会联系地址:

山东省济宁市任城区荷花路129号

Contact Address of the ethic committee:

No. 129, Lotus Road, Rencheng District, Jining City, Shandong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 156 5376 0125

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

济宁医学院附属医院

Primary sponsor:

The Affiliated Hospital of Jining Medical University

研究实施负责(组长)单位地址:

山东省济宁市任城区荷花路129号

Primary sponsor's address:

No. 129, Lotus Road, Rencheng District, Jining City, Shandong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

Country:

China

Province:

Shandong

City:

单位(医院):

济宁医学院附属医院

具体地址:

山东省济宁市任城区荷花路129号

Institution
hospital:

The Affiliated Hospital of Jining Medical University

Address:

No. 129, Lotus Road, Rencheng District, Jining City, Shandong Province

经费或物资来源:

研究生课题

Source(s) of funding:

Postgraduate project

研究疾病:

术后恶心呕吐  

Target disease:

Postoperative Nausea and Vomiting

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

比较不同止吐药物联合应用对妇科腹腔镜手术术后恶心呕吐的防治作用,探索更精准、有效的防治手段,从而显著降低PONV的发生率,提高患者术后满意度,促进患者术后快速康复。  

Objectives of Study:

Compare the effects of different antiemetic drugs used in combination on the prevention and treatment of postoperative nausea and vomiting in gynaecological laparoscopic surgery, explore more precise and effective prevention and treatment methods, thereby significantly reducing the incidence of PONV, improving patient postoperative satisfaction, and promoting rapid postoperative recovery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、年龄18~65岁; 2、拟行妇科腹腔镜全麻手术的患者(腹腔镜卵巢和或输卵管手术,子宫切除和或子宫肌瘤切除手术,子宫病损切除术); 3、BMI18.5~28 kg/m^2; 4、ASA分级为I~II级; 5、无有关药物过敏史; 6、患者及家属知情同意,并签署知情同意书。

Inclusion criteria

1. Age 18–65 years; 2. Patients scheduled for gynecological laparoscopic surgery under general anesthesia (laparoscopic ovarian and/or fallopian tube surgery, hysterectomy and/or myomectomy, uterine lesion removal); 3. BMI 18.5–28 kg/m^2; 4. ASA classification I–II; 5. No history of drug allergies; 6. Patients and their families are informed and give consent, and sign the informed consent form.

排除标准:

1、术前合并严重感染,严重心功能不全,肝、肾功能不全; 2、手术前24h内使用已知对PONV的发生有影响的止吐药、糖皮质激素或精神药物; 3、慢性疼痛史,长期服用镇痛药或精神类药物史(包括阿片类、NSAIDs 和抗抑郁药); 4、患者术前有放化疗史; 5、患有糖尿病; 6、存在严重听力障碍/语言表达障碍/精神疾病,无法配合者。

Exclusion criteria:

1. Severe infection, severe heart failure, or liver and kidney dysfunction before surgery; 2. Use of antiemetic drugs, glucocorticoids, or psychiatric medications within 24 hours before surgery that are known to affect the occurrence of PONV; 3. History of chronic pain, long-term use of analgesics or psychiatric medications (including opioids, NSAIDs, and antidepressants); 4. History of radiotherapy or chemotherapy before surgery; 5. Diabetes; 6. Severe hearing impairment, language expression disorders, or mental illness, making patient unable to cooperate.

研究实施时间:

Study execute time:

From 2026-02-10 00:00:00 To 2027-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-02-10 00:00:00 To 2027-05-31 00:00:00

干预措施:

Interventions:

组别:

A组(地塞米松+昂丹司琼)

样本量:

64

Group:

Group A (dexamethasone + ondansetron)

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

B组(地塞米松+氟哌利多)

样本量:

64

Group:

Group B (Dexamethasone + Fluphenazine)

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

C组(地塞米松+盐酸戊乙奎醚)

样本量:

64

Group:

Group C (Dexamethasone + Pethidine Hydrochloride)

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

济宁 

Country:

China

Province:

Shandong

City:

Jining

单位(医院):

济宁医学院附属医院 

单位级别:

三甲 

Institution
hospital:

The Affiliated Hospital of Jining Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后恶心呕吐发生率

指标类型:

主要指标

Outcome:

Incidence of postoperative nausea and vomiting

Type:

Primary indicator

测量时间点:

1,6,24,48小时

测量方法:

Measure time point of outcome:

1,6,24,48 hours

Measure method:

指标中文名:

术后恶心呕吐严重程度

指标类型:

主要指标

Outcome:

Postoperative nausea and vomiting severity

Type:

Primary indicator

测量时间点:

1,6,24,48小时

测量方法:

Measure time point of outcome:

1,6,24,48 hours

Measure method:

指标中文名:

补救性止吐药使用情况

指标类型:

次要指标

Outcome:

Salvage antiemetics use

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

恢复质量Q15

指标类型:

次要指标

Outcome:

Restore quality Q15

Type:

Secondary indicator

测量时间点:

24小时

测量方法:

Measure time point of outcome:

24 hours

Measure method:

指标中文名:

术后首次排气时间

指标类型:

次要指标

Outcome:

The time of the first postoperative flatus

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件发生率

指标类型:

次要指标

Outcome:

Incidence of adverse events

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后疼痛评分(静息状态和咳嗽吞咽时)

指标类型:

次要指标

Outcome:

Postoperative pain score (at rest and when coughing and swallowing)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF;EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF;EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-02-03 16:38:04